Hoechst Marion Roussel's Arava Posts $21 Mil. In 1998 U.S. Sales
Executive Summary
Hoechst Marion Roussel's rheumatoid arthritis therapy Arava (leflunomide) garnered $21 mil. (DM 37 mil.) in U.S. sales since its launch in September, the firm reported at its review of annual financial results March 18 in Frankfurt.